pharma · Crohn's Disease · Ulcerative Colitis (UC)
AbbVie
AbbVie is a pharma organization headquartered in Hamilton, CN. Primary therapeutic focus areas include Crohn's Disease, Ulcerative Colitis (UC), Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa. NovaPh
Company details
- Status
- Public
- HQ
- 1 Waukegan Road, North Chicago, Illinois 60064, US
- Employees
- 60,084
- Programs
- 41
- Drugs
- 32
- Patents
- 25
ABT-493
Phase 1 · small molecule · Hepatic Impairment
ABT-493 for Hepatic Impairment is a Phase 1 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).
Internal code M13-604
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AbbVie
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Hepatic Impairment
- Status
- completed
- Trials
- 1